Heterocyclic compounds and uses thereof
New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
Novartis AG
C C A A C C C C A C A A A A A
C07D C07D A61K A61K C07D C07D C07D C07D A61K C07D A61K A61K A61K A61P A61K
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Paul A. Yongjin Daniel Timothy Qiong Zheng Aaron Cynthia William R. Maureen Martin Jeff Zilin
Renhowe Xu Poon Machajewski Zhang Chen Smith Shafer Antonios-McCrea McKenna Sendzik Jin Huang